Lee Sung 4

What Happened
Lee Sung, Chief Financial Officer of Cytokinetics, reported a sale of 4,935 shares on 2026-03-17 at $62.15 per share, totaling $306,710. The filing notes this was a compelled sell-to-cover to satisfy tax withholding tied to RSU vesting, not an independent market-timing purchase.

Key Details

• Transaction date: 2026-03-17; Form 4 filed: 2026-03-18 (filed the next day, within the standard 2-business-day window).
• Price: $62.15 per share; Shares sold: 4,935; Gross proceeds: $306,710.
• Transaction type: Sale (open market/private sale per report).
• Footnote: F1 — Company compelled sell-to-cover to satisfy tax withholding obligations attributable to RSU vesting.
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context
Sell-to-cover transactions are common when restricted stock units vest and the employer sells a portion of the shares to cover taxes; they typically reflect tax mechanics rather than a change in the insider’s view of the company. This is a routine insider sale documented promptly on a Form 4.